Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo

Details Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo

1989-03-23

1991-10-15

Fan, Jane T.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514361, 514375, 514253, 514314, 514278, 546271, 546 15, 546174, 548127, 548218, 544238, A61K 3144, C07D49804

Patent

active

050575260

ABSTRACT:
Compounds of the formula I ##STR1## wherein R is a hydrogen atom or an alkyl radical, R.sub.1 is a hydrogen atom or an alkyl, alkenyl or a cycloalkyl radical, R.sub.2 is a hydrogen atom or an alkyl, alkenyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl or hydrazinocarbonyl radical or R.sub.1 and R.sub.2, together with the carbon atom to which they are attached, form a cycloalkyl ring, X is a valency bond or an alkylene or vinylene radical, R.sub.3 is an aromatic heterocyclic five-membered ring containing 1 to 4 heteroatoms or pyridinyl which the five- and six-membered rings are optionaly substituted one or more times by alkyl, alkoxy, alkoxycarbonyl, carboxyl, alkylthio, hydroxyl, nitro, amino, halogen or cyano and the tautomers, optically-active forms and physiologically acceptable salts thereof with inorganic and organic acids.
These compounds are useful for treatment of immunological disorders or autoimmune diseases such as aids/ARC, rheumatoid arthritis, lupus erythematosus and to suppress rejection reactions after organ/tissue transplants.

REFERENCES:
patent: 4695567 (1987-09-01), Mertens et al.
patent: 4730003 (1988-03-01), Von der Saal et al.
K. H. Fye, "Rheumatic Diseases", ch. 26 of D. P. Stites et al., Basic and Clinical Immunology, pp. 430-459 (4th ed. 1982) (Fye).
I. M. Roitt et al., Immunology, pp. 8.3 and 23.11 (1989) ("Roitt").
N. F. Rothfield, "The Relation of Immunoglobulin Class, Pattern of Antinuclear Antibody, and Complement-Fixing Antibodies to DNA in Sera from Patients with Systemic Lupus Erythematosus", J. Clin. Invest. 46, 1785-94 (1967) (Rothfield).
M. Reichlin et al., "Antigens and Antibodies Characteristic of Systemic Lupus Erythematosus", Bull. Rheum. Dis. 24, 756-60 (1974) (Reichlin).
J. L. Abruzzo et al., "IgG and Anti-IgG Antibodies in Rheumatoid Arthritis and Certain Other Conditions", Ann. Rheum. Dis. 33, 258-61 (1974) (Abruzzo).
Bichner, Uwe, Nature 324:307 (1986).
Klatzman et al., Nature, 319:10-11 (1986).
Klatzman et al., Immunology Today, 7:291-296 (1986).
Van Der Lilie Brit J. Hemat., 67:109-114 (1987).
Saxon, Andrew et al., J. Allergy Clin. Immunol., 81:796-802 (1988).

Affiliated with

Also associated with

Rating

Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active pyridinyl substituted 5,7-dihydropyrrolo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-991523